The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | n/a | 79 | 43 |
Growth
|
n/a | n/a | 71 | 73 |
Safety
|
n/a | n/a | 21 | 21 |
Sentiment
|
n/a | n/a | 6 | 41 |
|
n/a | n/a | 72 | 45 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
n/a | n/a | 71 | 92 |
Opinions Change
|
n/a | n/a | 50 | 50 |
Pro Holdings
|
n/a | n/a | 1 | 5 |
Market Pulse
|
n/a | n/a | 1 | 42 |
Sentiment
|
n/a | n/a | 6 | 41 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | n/a | 79 | 43 |
Growth
|
n/a | n/a | 71 | 73 |
|
n/a | n/a | 21 | 21 |
Combined
|
n/a | n/a | 4 | 4 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
n/a | n/a | 94 | 53 |
Price vs. Earnings (P/E)
|
n/a | n/a | 100 | 3 |
Price vs. Book (P/B)
|
n/a | n/a | 94 | 98 |
Dividend Yield
|
n/a | n/a | 1 | 1 |
Value
|
n/a | n/a | 79 | 43 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
n/a | n/a | 100 | 100 |
Profit Growth
|
n/a | n/a | 4 | 4 |
Capital Growth
|
n/a | n/a | 95 | 99 |
Stock Returns
|
n/a | n/a | 1 | 21 |
Growth
|
n/a | n/a | 71 | 73 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
n/a | n/a | 32 | 13 |
Refinancing
|
n/a | n/a | 100 | 13 |
Liquidity
|
n/a | n/a | 21 | 21 |
|
n/a | n/a | 21 | 21 |
Discover high‑ranked alternatives to Pear Therapeutics and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.